| Property | Value |
|---|
|
?:abstract
|
-
BACKGROUND: The coronavirus disease 2019 (COVID-19) pandemic has affected almost 2.5 million people worldwide with almost 170,000 deaths reported to date. So far, there is scarce evidence for the current treatment options available for COVID-19. Vitamin C has previously been used for treatment of severe sepsis and septic shock. We reviewed the feasibility of using vitamin C in the setting of COVID-19 in a series of patients. METHODS: We sequentially identified a series of patients who were requiring at least 30% of FiO2 or more who received IV vitamin C as part of the COVID-19 treatment and analyzed their demographic and clinical characteristics. We compared inflammatory markers pre and post treatment including D-dimer and ferritin. RESULTS: We identified a total of 17 patients who received IV vitamin C for COVID-19. The inpatient mortality rate in this series was 12% with 17.6% rates of intubation and mechanical ventilation. We noted a significant decrease in inflammatory markers, including ferritin and D-dimer, and a trend to decreasing FiO2 requirements, after vitamin C administration. CONCLUSION: The use of IV vitamin C in patients with moderate to severe COVID-19 disease may be feasible.
|
|
?:creator
|
|
|
?:doi
|
|
|
?:doi
|
-
10.1080/14787210.2020.1794819
|
|
?:journal
|
-
Expert_review_of_anti-infective_therapy
|
|
?:license
|
|
|
?:pdf_json_files
|
-
document_parses/pdf_json/840ab64a8b2b14457bdffa0a9178480e97046be6.json
|
|
?:pmc_json_files
|
-
document_parses/pmc_json/PMC7441798.xml.json
|
|
?:pmcid
|
|
|
?:pmid
|
|
|
?:pmid
|
|
|
?:publication_isRelatedTo_Disease
|
|
|
?:sha_id
|
|
|
?:source
|
|
|
?:title
|
-
The use of IV vitamin C for patients with COVID-19: a case series
|
|
?:type
|
|
|
?:year
|
|
![[This page as RDF]](https://research.tib.eu/covid-19/static/rdf-icon.gif){kind=icon}